SCHEMBL1301170

SCHEMBL1301170

O=C1Nc2cc(Cl)ccc2/C1=C\c1cccc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 4/20 0.54
CISD1 Q9NZ45 2/20 0.49
TTR P02766 1/20 0.49
PIM1 P11309 1/20 0.49
PIM2 Q9P1W9 1/20 0.49
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47
TUBA1A Q71U36 1/20 0.47
TUBA1C Q9BQE3 1/20 0.47
TUBB6 Q9BUF5 1/20 0.47
TUBB2B Q9BVA1 1/20 0.47
TUBB1 Q9H4B7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29875451 1.00 LRRK2 (0.54) LRRK2CISD1TTRPIM1PIM2
SCHEMBL1301174 1.00 LRRK2 (0.54) LRRK2CISD1TTRPIM1PIM2
SCHEMBL14674469 0.90 LRRK2 (0.68) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL1300997 0.90 LRRK2 (0.68) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL8205160 0.87 LRRK2 (0.65) LRRK2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL250592 0.87 LRRK2 (0.65) LRRK2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29443853 0.87 LRRK2 (0.65) LRRK2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL250593 0.87 LRRK2 (0.65) LRRK2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1300733 0.86 PDGFRB (0.56) CISD1TTRPIM1PIM2PLK4
SCHEMBL1300738 0.86 PDGFRB (0.56) CISD1TTRPIM1PIM2PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742121-B2 Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-06-03 US claimed
US-20130030173-A1 PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2013-01-31 US claimed
EP-2350001-A1 NOVEL BENZYLIDENE-INDOLINONE AND THEIR MEDICAL AND DIAGNOSTIC USES National University of Singapore (SG) 2011-08-03 EP claimed
WO-2010044753-A1 NOVEL BENZYLIDENE-INDOLINONE AND THEIR MEDICAL AND DIAGNOSTIC USES NATIONAL UNIVERSITY OF SINGAPORE (SG) 2010-04-22 WO claimed
CN-116621765-B Synthesis method and application of 2-indolone analogue containing alpha, beta-unsaturated ketone 贵州省天然产物研究中心 2023-10-13 CN disclosed
CN-116621765-A Synthesis method and application of 2-indolone analogue containing alpha, beta-unsaturated ketone 贵州省天然产物研究中心 2023-08-22 CN disclosed
CN-114057755-B Preparation method and application of iridoid aglycone-based spiro indolone compound 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2022-08-30 CN disclosed
CN-114057755-A Preparation method and application of iridoid aglycone-based spiro indolone compound 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2022-02-18 CN disclosed
US-20110269812-A1 NOVEL BENZYLIDENE-INDOLINONE AND THEIR MEDICAL AND DIAGNOSTIC USES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-11-03 US disclosed
EP-2350001-A1 NOVEL BENZYLIDENE-INDOLINONE AND THEIR MEDICAL AND DIAGNOSTIC USES National University of Singapore (SG) 2011-08-03 EP disclosed
WO-2010044753-A1 NOVEL BENZYLIDENE-INDOLINONE AND THEIR MEDICAL AND DIAGNOSTIC USES NATIONAL UNIVERSITY OF SINGAPORE (SG) 2010-04-22 WO disclosed
US-7638548-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-29 US disclosed
US-20080114013-A1 SPIROINDOLINONE DERIVATIVES LIU JIN-JUN 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269812-A1 NOVEL BENZYLIDENE-INDOLINONE AND THEIR MEDICAL AND DIAGNOSTIC USES SBK3, DMPK, PHKG2 LRRK2 191/4885CISD1 2020/4885TTR 3845/4885
US-20130030173-A1 PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN TP53, MDM2, CDKN1A LRRK2 963/4885CISD1 1459/4885TTR 4399/4885
US-20080114013-A1 SPIROINDOLINONE DERIVATIVES RB1, XPOT, PDK2 LRRK2 267/4885CISD1 1183/4885TTR 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.